The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Ruxolitinib plus azacitidine for myelofibrosis
Naval Daver
• 18 Dec 2018
Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, presents the results of a Phase II study of ruxolitinib in combination with azacitidine in patients with myelofibrosis (NCT01787487), which were reported at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
